摘要
目的观察尼妥珠单抗联合放化疗治疗局部晚期宫颈癌的疗效及不良反应。方法将72例Ⅱb～Ⅳa期宫颈癌患者随机分为2组。对照组采用调强放疗、腔内后装治疗及同期化疗,观察组加用尼妥珠单抗。治疗后3个月比较两组近期疗效及不良反应。结果观察组总有效率明显高于对照组（88.9%vs 69.4%,P〈0.05）。两组不良反应发生率差异无统计学意义（P〉0.05）。结论尼妥珠单抗联合放化疗可提高晚期宫颈癌疗效。
Objective To observe the clinical efficacy and adverse reactions of nimotuzumab and chemoradiotherapy in locally advanced cervical cancer. Methods Seventy-two patients with stage Ⅱb～Ⅳa cervical cancer were randomly divided into 2 groups：control group received intensity-modulated radiotherapy,intracavitary brachytherapy and simultaneous chemotherapy,while observation group accepted the additional nimotuzumab. The 3-month clinical efficacy and adverse reactions were compared between 2 groups. Results The overall efficacy was higher in observation group than in control group（88.9% vs 69.4%,P〈0.05）,while the rates of adverse reactions were insignificant（P〈0.05）. Conclusion Combined regimen with nimo-tuzumab and chemoradiotherapy can improve the therapeutic efficacy in patients with advanced cervical cancer.
出处
《广东医学院学报》
2015年第6期692-694,共3页
Journal of Guangdong Medical College
基金
佛山市科技攻关立项资助项目(No.2014AB000302)
